Mutations on OAS1 Genes
AssigneeKineta Two, LLC
InventorsShawn P. Iadonato, Charles L. Magness, P. Campion Fellin, Christina A. Scherer, Tory Hagen, Amy Olson
Life of this patent
Estimating the term…
Abstract
Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided.
Claims21
1-28. (canceled)
An oligoadenylate synthetase 1 protein consisting of the amino acid sequence of SEQ ID NO:1 having at least one amino acid modification at position 1, 24, 25, 28, 31, 36, 47, 53, 54, 64, 69, 74, 104, 108, 112, 113, 114, 115, 116, 117, 118, 119, 127, 130, 139, 142, 160, 161, 166, 175, 179, 226, 242, 246, 248, 250, 254, 274, 279, 282, 284, 288, 289, 292, 295, 314, 315, and/or 335, and wherein the amino acid at position 162 is Gly.
A therapeutic composition for treating or preventing infection by a virus in a mammal or for treating cancer in a mammal wherein the composition comprises a pharmaceutically acceptable carrier and an oligoadenylate synthetase 1 protein consisting of the amino acid sequence of SEQ ID NO:1 having at least one amino acid modification at position 1, 24, 25, 28, 31, 36, 47, 53, 54, 64, 69, 74, 104, 108, 112, 113, 114, 115, 116, 117, 118, 119, 127, 130, 139, 142, 160, 161, 166, 175, 179, 226, 242, 246, 248, 250, 254, 274, 279, 282, 284, 288, 289, 292, 295, 314, 315, and/or 335, and wherein the amino acid at position 162 is Gly.
An oligoadenylate synthetase 1 protein consisting of amino acids 1-353 of SEQ ID NO:2 ID NO:2, wherein the protein has at least one amino acid modification at position 1, 24, 25, 28, 31, 36, 47, 53, 54, 64, 69, 74, 104, 108, 112, 113, 114, 115, 116, 117, 118, 119, 127, 130, 139, 142, 160, 161, 166, 175, 179, 226, 242, 246, 248, 250, 254, 274, 279, 282, 284, 288, 289, 292, 295, 314, 315, 335, 347, 350, 352, and/or 353, and wherein the amino acid at position 162 is Gly.
Dependencies are inferred from the claim text.